ASH 2022 | Distinguishing early infections from CRS following CD19 CAR-T therapy for R/R B-NHL
In this video, Kai Rejeski, MD, LMU Munich, Munich, Germany, discusses research being conducted to help overcome the challenge of distinguishing between early infections and cytokine release syndrome (CRS) in the first 10 days after CAR-T infusion. Using routine and exploratory serum proteomics to evaluate inflammatory markers in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), the study found that in those with early infections, there were higher levels of procalcitonin, whereas CRS patients had higher levels of IL-6. Dr Rejeski also shares some insights into the use of the CAR-HEMATOTOX 10 (HT10) score to distinguish between CRS and early infection. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
